[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-337369-105":59,"doc-detail-337369-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","current-evidence-of-pd-1-and-pd-l1-immune-checkpoint-inhibitors-for-esophageal-cancer-an-updated-meta-analysis-and-synthesis-of-ongoing-clinical-trials","Current evidence of PD-1 and PD-L1 immune checkpoint inhibitors for esophageal cancer: an updated meta-analysis and synthesis of ongoing clinical trials","","Esophageal cancer has poor outcomes, with very low 5-year survival in advanced stages. This study evaluates the efficacy of programmed death-1 (PD-1) and programmed death-ligand 1 (PD-L1) inhibitors in esophageal cancer patients by analyzing phase III clinical trials. A PRISMA 2020-guided meta-analysis pooled 13 phase III trials with 6519 participants. Results show overall survival and objective response favor PD-1/PD-L1 inhibitors, while progression-free survival is not significantly affected.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/current-evidence-of-pd-1-and-pd-l1-immune-checkpoint-inhibitors-for-esophageal-cancer-an-updated-meta-analysis-and-synthesis-of-ongoing-clinical-trials/337369/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/current-evidence-of-pd-1-and-pd-l1-immune-checkpoint-inhibitors-for-esophageal-cancer-an-updated-meta-analysis-and-synthesis-of-ongoing-clinical-trials/337369.png","ImageObject",300,407,{"name":92,"@type":93},"Jiven","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-31","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":29},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What question does the meta-analysis address about esophageal cancer?","Question",{"text":112,"@type":113},"It assesses how well PD-1 and PD-L1 immune checkpoint inhibitors work for esophageal cancer patients by analyzing phase III clinical trials.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"Which outcomes favored PD-1/PD-L1 inhibitors, and which did not?",{"text":117,"@type":113},"Overall survival and the likelihood of achieving objective response favored PD-1/PD-L1 inhibitors, while progression-free survival was not significantly affected.",{"name":119,"@type":110,"acceptedAnswer":120},"How were eligible studies identified and analyzed?",{"text":121,"@type":113},"PubMed/MEDLINE, Web of Science, and Embase were searched through 6 December 2022, and the synthesis used PRISMA 2020 guidance with Review Manager 5.4.3.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},337369,1790656483,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":29,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},1099513958607,"https://ap-avatar.wpscdn.com/avatar/100002390cf8733938c?x-image-process=image/resize,m_fixed,w_180,h_180&k=1778829742770036399","TherapeuTic advances in  \nMedical Oncology Original Research  \nCurrent evidence of PD-1 and PD-L1 immune checkpoint inhibitors for esophageal cancer: an updated meta-analysis and synthesis of ongoing clinical trials  \nSaram Zafar, Rabbia Shehzadi, Hina Dawood, Moeez Maqbool, Azza Sarfraz  \nand Zouina Sarfraz  \nAbstract  \nBackground: Esophageal cancer (EC) is the sixth leading cause of cancer mortality worldwide, with a poor prognosis and a 5-year survival rate of 5% in advanced cases.  \nObjectives: To evaluate the efficacy of programmed death-1 (PD-1) and programmed deathligand 1 (PD-L1) inhibitors in EC patients by analyzing phase III clinical trials.  \nDesign: A meta-analysis following the PRISMA Statement 2020 guidelines.  \nMethods: PubMed/MEDLINE, Web of Science, and Embase were searched through 6 December 2022, and the analysis was conducted using Review Manager 5.4.3 (Cochrane) . Results: Out of 387 studies, 13 phase III clinical trials with 6519 participants were pooled.  \nOverall survival (OS) favored PD-1/PD-L1 inhibitors with a Cohen’s d of 0.28 (95% CI: 0.12–0.43; p = 0 . 0006), and the likelihood of achieving objective response also favored these inhibitors (OR: 2. 04, 95% CI: 1.68–2.48; p \u003C 0. 0001) .  \nConclusion: This meta-analysis provides strong evidence that PD-1/PD-L1 inhibitors combined with chemotherapy improve OS and objective response rate among patients with advanced EC but do not affect progression-free survival.  \nTrial registration: Open Science Framework: [osf.io/y27rx](osf.io/y27rx).  \nPlain language summary  \nCurrent status of PD-1 and PD-L1 immune checkpoint inhibitors in esophageal cancer: insights from an updated meta-analysis and ongoing clinical trials  \nEsophageal cancer is a significant global health concern with a low survival rate, especially in advanced cases. This study, following rigorous guidelines, analyzed data from 13 clinical trials involving over 6,500 participants to assess the effectiveness of PD-1 and PD-L1 inhibitors. The results suggest that combining these inhibitors with chemotherapy improves overall survival and the likelihood of positive treatment responses in advanced esophageal cancer patients. However, no significant impact on progression-free survival was observed. This meta-analysis provides valuable insights into the current state of immune checkpoint inhibitors for esophageal cancer, offering hope for improved treatment outcomes.  \nKeywords: esophageal cancer, immune checkpoint inhibitors, immunotherapy, programmed cell death  \nReceived: 10 April 2023; revised manuscript accepted: 29 November 2023.  \nTherAdv Med Oncol 2024, Vol. 16: 1–15  \nDOI: 10. 1177/  \n17588359231221339 © The Author(s), 2024. Article reuse guidelines:  \n[sagepub.com/journals](sagepub.com/journals)permissions  \nCorrespondence to:  \nZouina Sarfraz  \nResearch & Publications, Fatima Jinnah Medical University, Queen’s Road, Mozang Chungi, Lahore, PB 54000, Pakistan  \n[zouinasarfraz@gmail.com](zouinasarfraz@gmail.com)[ ](zouinasarfraz@gmail.com)Saram Zafar  \nLahore Medical & Dental College, Lahore, Pakistan  \nRabbia Shehzadi  \nFatima Jinnah Medical University, Lahore, Pakistan  \nHina Dawood  \nAmeer Ud Din Medical College, Lahore, Pakistan  \nMoeez Maqbool  \nSheikh Zayed Medical College, Rahim Yar Khan, Pakistan  \nAzza Sarfraz  \nThe Aga Khan University, Karachi, Pakistan  \n[journals.sagepub.com/home/tam](journals.sagepub.com/home/tam) 1  \nCreative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License  \n([https://creativecommons.org/licenses/by-nc/4.0/](https://creativecommons.org/licenses/by-nc/4.0/)) which permits non-commercial use, reproduction and distribution of the work without further permission  \nprovided the original work is attributed as specified on the Sage and Open Access pages ([https://us.sagepub.com/en-us/nam/open-access-at-sage](https://us.sagepub.com/en-us/nam/open-access-at-sage)) .  \nIntroduction  ","cbCaipoG98bCHKQi","https://ap.wps.com/l/cbCaipoG98bCHKQi","pdf",2570201,15,"English","# Abstract\n## Background and Objectives\n## Design, Methods, and Results\n## Conclusion and Trial Registration\n# Introduction\n## Epidemiology and Treatment Landscape\n## Immunotherapy and PD-1/PD-L1 Biology","[{\"question\":\"What question does the meta-analysis address about esophageal cancer?\",\"answer\":\"It assesses how well PD-1 and PD-L1 immune checkpoint inhibitors work for esophageal cancer patients by analyzing phase III clinical trials.\"},{\"question\":\"Which outcomes favored PD-1/PD-L1 inhibitors, and which did not?\",\"answer\":\"Overall survival and the likelihood of achieving objective response favored PD-1/PD-L1 inhibitors, while progression-free survival was not significantly affected.\"},{\"question\":\"How were eligible studies identified and analyzed?\",\"answer\":\"PubMed/MEDLINE, Web of Science, and Embase were searched through 6 December 2022, and the synthesis used PRISMA 2020 guidance with Review Manager 5.4.3.\"}]","Current evidence of PD-1 and PD-L1 immune checkpoint inhibitors for esophageal cancer: an updated meta-analysis and synthesis of ongoing clinical trials | PDF",1790018844,38,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/0cce3d89e233e45f63820593650897a4.webp",983,1310,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b059bcd318e989b0e5802c80808a8055.webp",982,1309,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a4a3b7d5d3dc0c29afda7a407f9153db.webp",981,1308,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d8a6be79042ce624410e0cb5d3bdba85.webp",980,1306]